Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease.


Journal

Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 14 11 2018
accepted: 19 11 2018
pubmed: 28 11 2018
medline: 17 3 2020
entrez: 28 11 2018
Statut: ppublish

Résumé

There are no previous reports describing the fecal fungal microbiome of a Japanese population using advanced molecular techniques. In this study, we performed a molecular analysis on the fungal microbial community of a healthy Japanese population and patients with inflammatory bowel diseases (IBDs). Fecal samples were obtained from 18 patients with inactive ulcerative colitis (UC, n = 18), Crohn's disease (CD, n = 20) and healthy volunteers (n = 20). Bacterial and fungal microbiome was analyzed by sequencing of 16S rRNA and the internal transcribed spacer (ITS) region, respectively. 16S rRNA sequencing of the bacterial microbiome revealed that the α-diversity indicated by the Chao-1 and Shannon indices was significantly lower in CD patients compared to healthy controls and/or UC patients. Principal coordinate (PCo) analysis of the bacterial community revealed significant structural differences in microbiome among healthy controls, UC and CD patients (PERMANOVA P = 0.0001). ITS sequencing of the fungal microbiome indicated no significant differences in α-diversity between healthy controls and IBD patients. However, the overall structure of the fungal microbial community of CD patients was significantly different from those of healthy controls and UC patients (PERMANOVA = 0.03). At the genus level, the genus Saccharomyces was dominant and this was followed by the genus Sarocladium in healthy controls. The abundance of the genus Candida was significantly higher in CD patients than healthy controls and/or UC patients. The fecal fungal microbiome of a Japanese population differed considerably from that of a Western population. We identified fungal dysbiosis in Japanese patients with IBD.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
There are no previous reports describing the fecal fungal microbiome of a Japanese population using advanced molecular techniques. In this study, we performed a molecular analysis on the fungal microbial community of a healthy Japanese population and patients with inflammatory bowel diseases (IBDs).
PATIENTS AND METHODS METHODS
Fecal samples were obtained from 18 patients with inactive ulcerative colitis (UC, n = 18), Crohn's disease (CD, n = 20) and healthy volunteers (n = 20). Bacterial and fungal microbiome was analyzed by sequencing of 16S rRNA and the internal transcribed spacer (ITS) region, respectively.
RESULTS RESULTS
16S rRNA sequencing of the bacterial microbiome revealed that the α-diversity indicated by the Chao-1 and Shannon indices was significantly lower in CD patients compared to healthy controls and/or UC patients. Principal coordinate (PCo) analysis of the bacterial community revealed significant structural differences in microbiome among healthy controls, UC and CD patients (PERMANOVA P = 0.0001). ITS sequencing of the fungal microbiome indicated no significant differences in α-diversity between healthy controls and IBD patients. However, the overall structure of the fungal microbial community of CD patients was significantly different from those of healthy controls and UC patients (PERMANOVA = 0.03). At the genus level, the genus Saccharomyces was dominant and this was followed by the genus Sarocladium in healthy controls. The abundance of the genus Candida was significantly higher in CD patients than healthy controls and/or UC patients.
CONCLUSION CONCLUSIONS
The fecal fungal microbiome of a Japanese population differed considerably from that of a Western population. We identified fungal dysbiosis in Japanese patients with IBD.

Identifiants

pubmed: 30478724
doi: 10.1007/s00535-018-1530-7
pii: 10.1007/s00535-018-1530-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-159

Références

Gastroenterology. 1976 Mar;70(3):439-44
pubmed: 1248701
N Engl J Med. 2005 Dec 8;353(23):2462-76
pubmed: 16339095
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Med Mycol. 2007 Dec;45(8):691-700
pubmed: 17885943
J Infect Dis. 2008 Apr 1;197(7):972-80
pubmed: 18419533
Br J Nutr. 2009 Nov;102(9):1324-33
pubmed: 19566967
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
New Phytol. 2010 Apr;186(2):281-5
pubmed: 20409185
PLoS Pathog. 2010 Apr 22;6(4):e1000758
pubmed: 20421940
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
Gastroenterology. 2010 Dec;139(6):1844-1854.e1
pubmed: 20816835
Inflamm Bowel Dis. 2011 Jan;17(1):179-84
pubmed: 20839241
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Inflamm Bowel Dis. 2012 May;18(5):968-84
pubmed: 21936031
Science. 2012 Jun 8;336(6086):1314-7
pubmed: 22674328
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Gastroenterology. 2013 Sep;145(3):591-601.e3
pubmed: 23732773
Genome Med. 2013 Jul 30;5(7):63
pubmed: 23899327
Bioinformatics. 2014 Nov 1;30(21):3123-4
pubmed: 25061070
Nestle Nutr Inst Workshop Ser. 2014;79:29-39
pubmed: 25227293
J Crohns Colitis. 2016 Mar;10(3):296-305
pubmed: 26574491
Gut. 2017 Jun;66(6):1039-1048
pubmed: 26843508
DNA Res. 2016 Apr;23(2):125-33
pubmed: 26951067
Biosci Biotechnol Biochem. 2016 Dec;80(12):2450-2458
pubmed: 27581276
Gastroenterology. 2017 Feb;152(2):327-339.e4
pubmed: 27769810
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Gastroenterology. 2017 Feb;152(2):313-321.e2
pubmed: 27793607
J Gastroenterol. 2017 Feb;52(2):141-150
pubmed: 27832357
J Gastroenterol. 2018 Jan;53(1):95-106
pubmed: 28852861
Microb Ecol. 2018 May;75(4):821-829
pubmed: 29110065
Front Microbiol. 2018 Sep 25;9:2247
pubmed: 30319571
Mol Ecol. 1993 Apr;2(2):113-8
pubmed: 8180733

Auteurs

Takayuki Imai (T)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Ryo Inoue (R)

Laboratory of Animal Science, Department of Agriculture and Life Science, Kyoto Prefectural University, Kyoto, 606-8522, Japan.

Yuki Kawada (Y)

Laboratory of Animal Science, Department of Agriculture and Life Science, Kyoto Prefectural University, Kyoto, 606-8522, Japan.

Yasuhiro Morita (Y)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Osamu Inatomi (O)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Atsushi Nishida (A)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Shigeki Bamba (S)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Masahiro Kawahara (M)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan.

Akira Andoh (A)

Department of Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, 520-2192, Japan. andoh@belle.shiga-med.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH